Granules India’s Paracetamol API facility completes USFDA inspection

16 Jun 2014 Evaluate

Granules India’s Paracetamol facility has successfully passed a USFDA inspection without any 483 observations. This facility has the world’s largest single API production line by volume.

Granules’ four API facilities have successfully passed USFDA inspections in the past 12 months. All of the company’s facilities including its finished dosage and PFI facility are approved by leading regulatory agencies including the USFDA, EDQM, Health Canada and Korean FDA.

Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.

Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.